Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2013; 5(01): 01-04
DOI: 10.4103/0974-2727.115895
Invited Editorial

Promoting Affordable and Quality Tuberculosis Testing in India

Madhukar Pai
McGill International TB Centre and Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
07 April 2020

© 2013.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Udwadia ZF. MDR, XDR, TDR tuberculosis: Ominous progression. Thorax 2012;67:286-8.
  • 2 Sachdeva KS, Kumar A, Dewan P, Satyanarayana S. New Vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access-"Reaching the un-reached". Indian J Med Res 2012;135:690-4.
  • 3 Kapoor SK, Raman AV, Sachdeva KS, Satyanarayana S. How Did the TB patients reach DOTS services in Delhi? A study of patient treatment seeking behavior. PLoS One 2012;7:e42458.
  • 4 Satyanarayana S, Nair SA, Chadha SS, Shivashankar R, Sharma G, Yadav S, et al. From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community based survey of 30 districts. PLoS One 2011;6:e24160.
  • 5 Jarosawlski S, Pai M. Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Glob Health 2012;2:39-50.
  • 6 Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: Has anything changed in two decades? PLoS One 2010;5:e12023.
  • 7 Singh S, Katoch VM. Commercial serological tests for the diagnosis of active tuberculosis in India: Time for introspection. Indian J Med Res 2011;134:583-7.
  • 8 Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: An updated systematic review and meta-analysis. PLoS Med 2011;8:e1001062.
  • 9 World Health Organization. Policy statement: Commercial serodiagnostic tests for diagnosis of tuberculosis. In Geneva: World Health Organization; 2011.
  • 10 World Health Organization. Policy statement: Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. In Geneva: World Health Organization; 2011.
  • 11 Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: Systematic review and meta-analysis. J Infect Dis 2011;204(Suppl 4):S1120-9.
  • 12 World Health Organization. Policy statement: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. In Geneva: World Health Organization; 2011.
  • 13 Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013;1:CD009593.
  • 14 Policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, 2008. Available from: http://www.who.int/tb/laboratory/policy_statements/en/index.html [Last accessed on 2013 Jun 17].
  • 15 Kay M. Private firms form initiative to offer accurate and affordable TB tests. BMJ 2013;346:f2161.